300009: Anhui Anke Biotechnology (Group) Co., Ltd. - Summary | Jitta

Anhui Anke Biotechnology (Group) Co., Ltd.

CHN:300009

Price
CN¥8.52
Loss Chance
44.6%
6.69JITTA SCORE
91.21%Over Jitta Line
Jitta Ranking
58 / 486
617 / 5,278
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (50)
Recent Business Performance (73)
Financial Strength (95)
Return to Shareholders (56)
Competitive Advantage (66)
Jitta Signs
Revenue and EarningConsistent
Operating MarginConsistent
Debt LevelLow Long Term Debt
Dividend PayoutEvery year
Interest Coverage RatioVery Good
SG&A to SalesDecreasing
Key Stats
Jitta Score
Jitta Line
6.69
91.21%
3.62
> 1,000%
4.26
> 1,000%
Biotechnology
7.64
8.97%
5.12
> 1,000%
6.09
29.45%
COMPANY DESCRIPTION
Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. It offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. The company provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life detection, sperm staining detection, sperm acrosin detection, immunohistochemical, sperm DNA fragmentation staining, leptin, and immunohistochemical diagnostic kits. In addition, it offers adhesive plasters, oral solutions, topical preparations, and ointments; peptide APIs; beauty care products, including anti-aging, masks, essential liquids, and mouthwash; and sybthetic drugs in the form of oral powders, dripping pills, and tablets and capsules. Further, the company provides autosomal, sex chromosome, and other kits; paternity testing, tumor biological immunotherapy technology, and DNA testing services. Additionally, the company offers monoclonal antibody drugs, such as Trastuzumab to treat patients with breast and gastric cancers under the ANTRASTUIN brand; Bevacizumab, an anti-VFDF product; ANKEBIO anti-PD1; and anti-covid19 products. The company was founded in 2000 and is based in Hefei, China.